H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $30. The company’s shares opened today at $18.30.
According to TipRanks.com, White is a 5-star analyst with an average return of 25.6% and a 55.8% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $25.40 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.39 and a one-year low of $8. Currently, Karyopharm Therapeutics has an average volume of 596.5K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
